Bravoxin 10 Suspension For Injection For Cattle And Sheep
Revised: May 2014
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Bravoxin10suspension for injection for cattle and sheep
Tribovax 10 (IE)
Polibascol 10 (ES)
Tribovax vet (NO)
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose of vaccine contains:
C. perfringens type A () toxoid
C. perfringens type B & C (β) toxoid
C. perfringens type D (ε) toxoid
C. chauvoei whole culture
C. novyi toxoid
C. septicum toxoid
C. tetani toxoid
C. sordellii toxoid
C. haemolyticum toxoid
Aluminium potassium sulphate (alum)
3,026 – 4,094 ppm
≤ 0.5 mg/ml
* ELISA According to Ph.Eur.
1In House ELISA
** Guinea pig challenge test according to Ph.Eur.
#In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Suspension for injection
Light brown aqueous suspension that settles on storage
4. CLINICAL PARTICULARS
Sheep and cattle.
4.2 Indications for use, specifying the target species
For the active immunisation of sheep and cattle against disease associated withinfections caused by Clostridium perfringenstype A, C. perfringens type B, C. perfringenstype C, C. perfringenstype D, Clostridium chauvoei, Clostridium novyi type B, Clostridium septicum,Clostridium sordelliiand Clostridium haemolyticumand against tetanus caused by Clostridium tetani.
For the passive immunisation of lambs and calves againstinfections caused by the above mentioned clostridial species (except C. haemolyticum in sheep).
Onset of immunity:
Two weeks after the primary vaccination course.
Duration of active immunity:
An anamnestic humoral immune response (immunological memory) to all components was demonstrated 12 months following the primary course of vaccination.
As demonstrated by serology/persistent antibody titre only:
Sheep: 12 months against C. perfringens type A, B, C and D,
C. novyitype B, C. sordellii, C. tetani
< 6 months against C. septicum, C. haemolyticum, C.
Cattle: 12 months against C. tetani and C. perfringens type D
< 12 months against C. perfringens type A, B and C
< 6 months against C. novyi type B, C. septicum, C.
sordellii, C. haemolyticum, C. chauvoei
Duration of passive immunity:
As demonstrated by serology/persistent antibody titreonly:
For lambs: At least 2 weeks for C. septicum and C. chauvoei
At least 8 weeks for C. perfringenstype B and C.
Perfringens type C
At least 12 weeks for C. perfringenstype A, C.
perfringenstype D, C. novyitype B, C. tetaniand C. sordellii
No passive immunity was observed for C. haemolyticum.
For calves: At least 2 weeks for C. sordelliiandC. haemolyticum
At least 8 weeks for C. septicumand C. chauvoei
At least 12
weeks for C. perfringenstype A,
C. perfringenstype B, C. perfringenstype C, C.
perfringenstype D, C. novyitype B, and C. tetani
Do not vaccinate sick or immunodeficient animals.
4.4 Special warnings for each target species
The effectiveness of the vaccine in providing passive immunity to young lambs and calves depends on these animals ingesting adequate amounts of colostrum on the first day of life.
Clinical trials have demonstrated that the presence of maternal antibodies (MDA), particularly against C. tetani, C. novyitype B, C. perfringenstype A (calves only), C. chauvoei(lambs only) and C. perfringenstype D may reduce the antibody response to vaccination in young lambs and calves. Therefore, to ensure an optimal response in young animals with high levels of MDA, the primary vaccination should be delayed until the levels wane (which is after about 8-12 weeks of age, see section 4.2).
Special precautions for use
Special precautions for use in animals
In the event of an anaphylactic reaction appropriate treatment such as adrenaline should be administered without delay.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In the case of accidental self-injection, encourage bleeding and wash the area immediately with water. If a local reaction develops, seek medical advice showing the package insert or the label to the physician.
Adverse reactions (frequency and seriousness)
75 - 100% of animals vaccinated with Bravoxin 10 may experience reactions to vaccination.
Most commonly reported adverse reactions are localised swelling or induration at the injection site but may also include mildhyperthermia, abscess or other reaction in the underlying tissues at the injectionsite.
Swelling at the injection site occurs in the majority of animals. This may reach up to a mean value of 6 cm in sheep and 15 cm diameter in cattle; occasionally reactions of up to 25 cm diameter may be seen in cattle.
Most local reactions resolve within 3-6 weeks in sheep and in less than 10 weeks in cattle, but may persist longer in a minority of animals.
An abscess may develop in some animals.
Vaccination may give rise to reactions in the underlying tissues at the injection site.
Skin discolouration at the injection site (which returns to normal as the local reaction resolved) may occur.
Localised pain at the injection site for 1-2 days post first vaccination may occur.
The local reactions do not affect the general health, demeanour, feeding or weight gain of the animals.
4.7 Use during pregnancy and lactation
No side effects other than those described under 4.6 were seen when the
vaccine was used in sheep and cattle between 8 and 2 weeks prior to parturition.
In the absence of specific data, the use of the vaccine is not recommended during the first or second third of pregnancy.
Avoid stress in pregnant ewes and cows.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
4.9 Amounts to be administered and administration route
Sheep – from 2 weeks of age
Dose- 1 ml
Cattle – from 2 weeks of age
Dose– 2 ml
Administration:By subcutaneous injection at a suitable site. The recommended site is the loose skin on the side of the neck.
Shake well before use.
Syringes and needles should be sterile before use and the injection should be made through an area of clean, dry skin taking precautions against contamination.
Primary vaccination:Two doses should be administered, 4-6 weeks apart.
Booster vaccination:A single dose should be administered at 6 to 12 month intervals .
Use in pregnancy
To provide passive protection of the offspring, via the colostrum, a single booster dose should be administered between 8 and 2 weeks before parturition, provided that animals have received a full primary vaccination course before pregnancy.
Overdose (symptoms, emergency procedures, antidotes)
In calves and lambs, local reactions may increase slightly if twice the recommended dose is administered (refer to section 4.6).
5. IMMUNOLOGICAL PROPERTIES
To stimulate active immunity in sheep and cattle against C. chauvoei and the toxins of Clostridium perfringenstype A, C. perfringens type B, C. perfringens type C, C. perfringenstype D, C. novyi, C. septicum, C. tetani, C.sordellii, andC. haemolyticumcontained in the vaccine.
To provide passive immunity via the colostrum against the above clostridial infections in young lambs and calves
ATCvet code: QI02AB01
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Aluminium potassium sulphate (alum)
Sodium Chloride (0.85% solution)
Do not mix with any other veterinary medicinal product.
Shelf-life of the veterinary medicinal product as packaged for sale: 30 months
Shelf-life after first opening the immediate packaging: 8 hours.
6.4 Special precautions for storage
Store and transport refrigerated (2 °C - 8 °C).
Protect from light.
Do not freeze.
6.5 Nature and composition of immediate packaging
Cardboard box with 1 flexible low density polyethylene bottle of 20, 50 or 100 ml with a pharmaceutical grade halogenobutyl rubber bung held in place with an aluminium seal.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
MARKETING AUTHORISATION HOLDER
Intervet UK Ltd
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
Date: 1 December 2008
10. DATE OF REVISION OF THE TEXT
Date: May 2014
Page 6 of 6